Liquid FSI

Liquid FSI is a biotechnology company focused on developing advanced liquid biopsy technologies for early cancer detection and monitoring. The company's core innovation is its proprietary Liquid-FSI platform, which utilizes high-throughput flow cytometry and microfluidics to isolate and analyze rare circulating tumor cells (CTCs) and other biomarkers from blood samples. By providing a non-invasive alternative to traditional tissue biopsies, Liquid FSI aims to improve patient outcomes through more frequent and accurate monitoring of disease progression and treatment response. The technology is designed to offer high sensitivity and specificity, potentially enabling the detection of cancer at its earliest, most treatable stages.